Files in this item
Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation
Item metadata
dc.contributor.author | Benek, Ondrej | |
dc.contributor.author | Vaskova, Michaela | |
dc.contributor.author | Miskerikova, Marketa | |
dc.contributor.author | Schmidt, Monika | |
dc.contributor.author | Andrys, Rudolf | |
dc.contributor.author | Rotterova, Aneta | |
dc.contributor.author | Skarka, Adam | |
dc.contributor.author | Hatlapatkova, Jana | |
dc.contributor.author | Karasova, Jana Zdarova | |
dc.contributor.author | Medvecky, Matej | |
dc.contributor.author | Hroch, Lukas | |
dc.contributor.author | Vinklarova, Lucie | |
dc.contributor.author | Fisar, Zdenek | |
dc.contributor.author | Hroudova, Jana | |
dc.contributor.author | Handl, Jiri | |
dc.contributor.author | Capek, Jan | |
dc.contributor.author | Rousar, Tomas | |
dc.contributor.author | Kobrlova, Tereza | |
dc.contributor.author | Dolezal, Rafael | |
dc.contributor.author | Soukup, Ondrej | |
dc.contributor.author | Aitken, Laura | |
dc.contributor.author | Gunn-Moore, Frank | |
dc.contributor.author | Musilek, Kamil | |
dc.date.accessioned | 2024-06-27T23:43:20Z | |
dc.date.available | 2024-06-27T23:43:20Z | |
dc.date.issued | 2023-10-05 | |
dc.identifier | 289931390 | |
dc.identifier | a91346d6-6015-41e7-8bf7-7b2841477b6f | |
dc.identifier | 85163144943 | |
dc.identifier.citation | Benek , O , Vaskova , M , Miskerikova , M , Schmidt , M , Andrys , R , Rotterova , A , Skarka , A , Hatlapatkova , J , Karasova , J Z , Medvecky , M , Hroch , L , Vinklarova , L , Fisar , Z , Hroudova , J , Handl , J , Capek , J , Rousar , T , Kobrlova , T , Dolezal , R , Soukup , O , Aitken , L , Gunn-Moore , F & Musilek , K 2023 , ' Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation ' , European Journal Of Medicinal Chemistry , vol. 258 , 115593 . https://doi.org/10.1016/j.ejmech.2023.115593 | en |
dc.identifier.issn | 0223-5234 | |
dc.identifier.other | RIS: urn:65B00772F81A87A3ED08FF81E7FB14DA | |
dc.identifier.other | ORCID: /0000-0003-3422-3387/work/138326677 | |
dc.identifier.other | ORCID: /0000-0001-7259-4491/work/138326710 | |
dc.identifier.uri | https://hdl.handle.net/10023/30049 | |
dc.description | Funding: This study was supported by the Ministry of Education, Youth, and Sports of the Czech Republic (project ESF no. CZ.02.1.01/0.0/0.0/18_069/0010054), by the University of Hradec Kralove (Faculty of Science, no. SV2103‐2022), by Charles University, Prague, Czech Republic (project Cooperatio, research area Neurosciences), by the project MH CZ-DRO VFN64165, and by MH CZ - DRO (UHHK, 00179906), by the Ministry of Defence of the Czech Republic (Faculty of Military Health Sciences Hradec Kralove) under the grant entitled the “Long-term organization development plan - Medical Aspects of Weapons of Mass Destruction”, and by the RS MacDonald Charitable Trust and Rosetrees Trust. | en |
dc.description.abstract | 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) is a multifunctional mitochondrial enzyme and putative drug target for the treatment of various pathologies including Alzheimer's disease or some types of hormone-dependent cancer. In this study, a series of new benzothiazolylurea-based inhibitors were developed based on the structure-activity relationship (SAR) study of previously published compounds and predictions of their physico-chemical properties. This led to the identification of several submicromolar inhibitors (IC50 ∼0.3 μM), the most potent compounds within the benzothiazolylurea class known to date. The positive interaction with 17β-HSD10 was further confirmed by differential scanning fluorimetry and the best molecules were found to be cell penetrable. In addition, the best compounds weren't found to have additional effects for mitochondrial off-targets and cytotoxic or neurotoxic effects. The two most potent inhibitors 9 and 11 were selected for in vivo pharmacokinetic study after intravenous and peroral administration. Although the pharmacokinetic results were not fully conclusive, it seemed that compound 9 was bioavailable after peroral administration and could penetrate into the brain (brain-plasma ratio 0.56). | |
dc.format.extent | 18 | |
dc.format.extent | 3016906 | |
dc.language.iso | eng | |
dc.relation.ispartof | European Journal Of Medicinal Chemistry | en |
dc.subject | Amyloid-binding alcohol dehydrogenase (ABAD) | en |
dc.subject | Alzheimer's disease | en |
dc.subject | 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) | en |
dc.subject | Enzyme inhibition | en |
dc.subject | Pharmacokinetics | en |
dc.subject | RM Therapeutics. Pharmacology | en |
dc.subject | QD Chemistry | en |
dc.subject | ATC-NDAS | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject | AC | en |
dc.subject | MCC | en |
dc.subject.lcc | RM | en |
dc.subject.lcc | QD | en |
dc.title | Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation | en |
dc.type | Journal article | en |
dc.contributor.sponsor | Rosetrees Trust | en |
dc.contributor.institution | University of St Andrews. School of Biology | en |
dc.contributor.institution | University of St Andrews. Biomedical Sciences Research Complex | en |
dc.contributor.institution | University of St Andrews. Sir James Mackenzie Institute for Early Diagnosis | en |
dc.contributor.institution | University of St Andrews. Centre for Biophotonics | en |
dc.contributor.institution | University of St Andrews. Institute of Behavioural and Neural Sciences | en |
dc.identifier.doi | 10.1016/j.ejmech.2023.115593 | |
dc.description.status | Peer reviewed | en |
dc.date.embargoedUntil | 2024-06-28 | |
dc.identifier.grantnumber | A1163 | en |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.